How should acute Plasmodium vivax malaria be managed, including blood-stage treatment, radical cure, and special considerations such as chloroquine resistance, pregnancy, G6PD deficiency, and infant dosing?

Management of Plasmodium vivax Malaria

For chloroquine-sensitive P. vivax, treat with chloroquine 25 mg/kg over 3 days (600 mg, 600 mg, 300 mg at 0,24,48 hours) followed by primaquine 15 mg daily for 14 days after confirming normal G6PD status; for chloroquine-resistant strains, use artemisinin-based combination therapy (ACT) such as artemether-lumefantrine or dihydroartemisinin-piperaquine for blood-stage treatment, followed by the same primaquine regimen for radical cure.

Blood-Stage Treatment

Chloroquine-Sensitive Areas

• Adults: Chloroquine 1,500 mg total dose (25 mg/kg) over 3 days: 600 mg at 0 hours, 600 mg at 24 hours, 300 mg at 48 hours 1, 2
• Children: 25 mg/kg total over 3 days: 10 mg/kg, 10 mg/kg, 5 mg/kg at 0,24,48 hours 1

Chloroquine-Resistant Areas

Chloroquine resistance in P. vivax is documented in Papua New Guinea, Indonesia, and other regions 3, 2. When resistance is suspected:

• First-line alternatives: Artemether-lumefantrine (AL) or dihydroartemisinin-piperaquine (DHA-PPQ) 4
• Monitor treatment response: If symptoms persist 48-72 hours after chloroquine initiation, switch to second-line therapy 1
• DHA-PPQ is preferred over AL due to piperaquine's longer half-life providing better post-treatment prophylaxis 4

Radical Cure (Hypnozoite Elimination)

Standard Primaquine Regimen

Primaquine 0.25 mg/kg/day (15 mg adult dose) for 14 days is the gold standard for preventing relapse 5, 6. This regimen achieves 99.1% hypnozoiticidal efficacy 6.

Critical caveat: G6PD testing is mandatory before primaquine administration 1, 2. Primaquine causes life-threatening hemolysis in G6PD-deficient individuals 1, 7.

Alternative Primaquine Regimens

• 7-day regimen (0.5 mg/kg/day): 96.3% efficacy but higher relapse risk than 14-day course 6
• Shorter courses are inadequate: 5-day and 3-day regimens show significantly higher relapse rates (RR 10.05 and 3.18 respectively) 5
• Weekly dosing: For populations with severe G6PD deficiency (notably Mediterranean variant), primaquine should not exceed 5 days at standard dosing 1. Alternative: 0.75 mg/kg weekly for 8 weeks under supervision 4, 5

Tafenoquine Alternative

Single-dose tafenoquine 300 mg (combined with chloroquine) offers 87.5% hypnozoiticidal efficacy 6. Requires:

• Quantitative G6PD testing showing >70% normal activity 8, 9
• Age ≥16 years 8
• Not approved for use with ACTs in most jurisdictions; FDA restricts coadministration to chloroquine only 4, 8

Special Populations

Pregnancy

Pregnant women cannot receive primaquine or tafenoquine due to unknown fetal G6PD status 10, 2, 11.

Management approach:

1. Acute treatment: Chloroquine 25 mg/kg over 3 days is safe throughout pregnancy 1
2. For chloroquine-resistant strains:
   • Artemether-lumefantrine is now recommended for 2nd and 3rd trimesters 3
   • First trimester: Use AL only when alternatives unavailable 3
   • Alternative: Quinine plus clindamycin (7-day course), though quinine requires hypoglycemia monitoring 3, 11
3. Suppressive therapy: Weekly chloroquine or hydroxychloroquine throughout pregnancy to prevent relapse 11
4. Postpartum radical cure: Perform quantitative G6PD testing after delivery, then administer primaquine if G6PD normal 10

G6PD Deficiency

Quantitative G6PD testing is essential before any 8-aminoquinoline 4, 8, 9. Qualitative tests are insufficient for heterozygous females who may have intermediate enzyme activity 11.

Management by G6PD status:

• Normal activity (>70%): Standard primaquine 14 days or tafenoquine single dose 8, 9
• Intermediate deficiency (30-70%, African A- variant): Weekly primaquine 0.75 mg/kg for 8 weeks with close monitoring 4
• Severe deficiency (<30%, Mediterranean B- variant): Primaquine contraindicated; use chloroquine suppression only 1, 4

Critical warning: If G6PD testing unavailable and primaquine administered, monitor closely for hemolysis (dark urine, pallor, jaundice, abdominal pain) 7. Hemolysis can be life-threatening and requires immediate primaquine discontinuation and supportive care 1, 7.

Infants and Young Children

• Chloroquine: 25 mg/kg total over 3 days (10-10-5 mg/kg dosing) 1
• Primaquine: 0.3 mg/kg/day for 14 days after G6PD testing 1
• Tafenoquine: Not approved for age <16 years 8

Treatment Monitoring

• Repeat thick smear if symptoms persist >3 days into therapy 1
• Follow-up: Instruct patients to return if fever recurs, suggesting relapse or treatment failure 1
• Adherence support: Supervised first dose, then provide remaining doses with clear instructions 1
• Single-dose tafenoquine eliminates adherence concerns inherent to 14-day primaquine regimens 8, 6

Common Pitfalls

1. Prescribing primaquine without G6PD testing: This is the most dangerous error, potentially causing fatal hemolysis 7, 9
2. Using inadequate primaquine duration: Shorter courses (<14 days at 0.25 mg/kg) have unacceptably high relapse rates 5, 6
3. Assuming chloroquine efficacy: Always verify local resistance patterns before prescribing 3, 2
4. Forgetting radical cure in pregnancy: Establish suppressive therapy plan and ensure postpartum G6PD testing and primaquine administration 10, 11
5. Inadequate patient education: Patients must understand primaquine dosing and recognize hemolysis symptoms 7